Table 1. Summary of currently recommended vaccines, numbers of primary and booster doses, and their schedule for different groups as of March 30, 2022.

Producta Individuals who are NOT moderately or severely immunocompromised Individuals who are moderately or severely immunocompromised
Primary seriesb Booster doseb Primary seriesb Booster doseb
Type of vaccine: mRNA vaccine
Adults (≥18 years) Pfizer/BioNTech Ages: 12 years and older (gray cap or purple cap) Primary 2 doses (30 μg [0.3 mL] each [purple or gray cap])Separate: Dose 1 and 2 by at least 3-8 weeks.c Booster Dose 1: At least 5 months after Dose 2 (30 μg [0.3 mL]).Booster Dose 2: At least 4 months after the first booster dose (30 μg [0.3 mL]) for individuals 50 years of age and older. Primary 3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks. Booster Dose 1: At least 3 months after Dose 3Booster Dose 2: At least 4 months after the first booster (optional)
Moderna Primary 2 doses (100 μg [0.5 mL] each [blue cap]).c Separate: Dose 1 and 2 by at least 4-8 weeks. Booster Dose 1: At least 5 months after Dose 2 (50 μg [0.25 mL] [red cap]).Booster Dose 2: At least 4 months after the first booster dose (50 μg [0.25 mL]). Primary 3 doses. Separate: Dose 1 and 2 by at least 4 weeks. Dose 2 and 3 by at least 4 weeks. Booster Dose 1: At least 3 months after Dose 3Booster Dose 2: At least 4 months after the first booster dose (optional)
Adolescents (12-17 years) Pfizer/BioNTech Ages: 12 years and older (gray cap or purple cap) Primary 2 doses (30 μg [0.3 mL] each [purple or gray cap]). Separate: Dose 1 and 2 by at least 3-8 weeks.c Booster Dose 1: At least 5 months after Dose 2 (30 μg [0.3 mL]).Booster Dose 2: At least 4 months after the first booster dose (30 μg [0.3 mL]) Primary 3 doses (30 μg [0.3 mL] each). Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks. Booster Dose 1: At least 3 months after Dose 3Booster Dose 2: At least 4 months after the first booster dose (optional)
Moderna Not recommended Not recommended Not recommended Not recommended
Children (5-11 years) Pfizer/BioNTech Ages: 5-11 years (Orange cap) Primary 2 doses (10 μg [0.2 mL] each [orange cap]). Separate: Dose 1 and 2 by at least 3 weeks Not recommended Primary 3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks. Not recommended
Young children (6 months -4 years) Not recommended Not recommended Not recommended Not recommended Not recommended
Infants (<2 years) Not recommended Not recommended Not recommended Not recommended Not recommended
Pregnant women Pfizer/BioNTech Primary 2 doses (30 μg [0.3 mL] each [purple or gray cap]) Separate: Dose 1 and 2 by at least 3-8 weeks. Booster Dose 1: At least 5 months after Dose 2 (30 μg [0.3 mL]). Not applicable Not applicable
Moderna Primary 2 doses (100 μg [0.5 mL] each [blue cap]). Separate: Dose 1 and 2 by at least 4-8 weeks. Booster Dose 1: At least 5 months after Dose 2 (50 μg [0.25 mL]). Not applicable Not applicable
Lactating women Pfizer/BioNTech Primary 2 doses (30 μg [0.3 mL] each [purple or gray cap]) Separate: Dose 1 and 2 by at least 3-8 weeks. Booster Dose 1: At least 5 months after Dose 2 (30 μg [0.3 mL]). Not applicable Not applicable
Moderna Primary 2 doses (100 μg [0.5 mL] each [blue cap]). Separate: Dose 1 and 2 by at least 4-8 weeks. Booster Dose 1: At least 5 months after Dose 2 (50 μg [0.25 mL]). Not applicable Not applicable
Type of vaccine: Viral vector vaccine
Adults (≥18 years) Janssend Primary 1 dose (5 × 1010 viral particles [0.5 mL]).b Booster Dose 1: At least 8 weeks after Dose 1 (5 × 1010 viral particles/mL [0.5 mL]).d Primary 2 doses (5 × 1010 viral particles/mL [0.5 mL]). Separate: Dose 1 and 2 by at least 28 daysd Dose 2 MUST be a mRNA vaccine.d Booster Dose 1: At least 8 weeks after Dose 2 (5 × 1010 viral particles/mL [0.5 mL]).d
Future plan
Young children (6 months -4 years) Pfizer/BioNTech Ages: 6 months -4 years (Maroon cap) Primary 2 doses (3 μg [0.2 mL] each [maroon cap]). Separate: Dose 1 and 2 by at least 3 weeks Not recommended Primary 3 doses. Separate: Dose 1 and 2 by at least 3 weeks. Dose 2 and 3 by at least 4 weeks. Not recommended
Administer Moderna or Pfizer-BioNTech COVID-19 Vaccine only, which are allowed under Emergency Use Instructions (EUI) for this dose. Janssen COVID-19 Vaccine is not under EUI for this dose.
Administer doses as close as possible to the recommended interval. It is not necessary to restart the series if the dose is given after the recommended interval; Administer the appropriate COVID-19 vaccine product based on the recipient’s age; COVID-19 vaccines may be administered on the same day as other vaccines. If multiple vaccines are administered at a single visit, administer each in a separate injection site; Complete the primary series using the same product. Every effort should be made to determine which vaccine product was received as the first dose. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose; and a different COVID-19 vaccine product than the primary series may be administered. An mRNA COVID-19 vaccine is preferred.
An 8 week interval may be optimal for some people, including males 12-39 years of age because of the small risk of myocarditis associated with mRNA COVID-19 vaccines. Vaccine effectiveness may also be increased with an interval longer than 3 (or 4 depending on document) weeks. See Interim Clinical Considerations for COVID-19 Vaccines (link below) for detailed information.
mRNA COVID-19 vaccines are preferred over the Janssen COVID-19 Vaccine for all vaccine-eligible people. However, the Janssen COVID-19 vaccine may be offered in some situations. For male adults with a history of myocarditis or pericarditis, a Janssen vaccine can be considered.